The study investigates whether statins, known for their anti-inflammatory properties, can reduce markers of HIV persistence and inflammation in individuals on long-term antiretroviral therapy (ART).
Researchers compared levels of specific HIV-related markers and immune activation between 303 statin users and non-users, finding no significant differences except for a slight variation in the IP-10 marker.
The conclusions suggest that statins do not significantly lower HIV persistence or immune activation in this cohort, indicating more research is necessary to determine their potential impact.